Fig. 8

A working mechanism model of AnxA6 roles in EGFR-expressing epithelial cancer cells. Comparison with the AnxA6 (left) in the un-stimulated cells, the SUMOylated AnxA6 with K299 SUMO1 conjugation (right) is prone to bind EGFR in response to EGF, which facilitates EGFR-PKCα complex formation to decrease the EGF-induced phosphorylation of EGFR-ERK1/2 and cyclin D1 expression, and finally contributes to the stronger inhibition of cell proliferation, migration and tumor growth in the epithelial cancer cells-xenografted nude mouse model, as well as improves gefitinib drug sensitivity , , .